Linneo Health And Phytocontrol Enter Into Medicinal Cannabis Clinical Analysis Collaboration Agreement

Linneo Health and Phytocontrol have signed an exclusive clinical analysis collaboration agreement. The agreement gives Linneo Health access to Phytocontrol’s clinical analysis capabilities and allows both businesses to progress new developments and collaborations within the medicinal cannabis sector.

Through this collaboration, Linneo Health and Phytocontrol will exclusively develop enhanced methods for pesticide and active materials analyses that will further Linneo Health’s global reach and support entry into new medicinal cannabis markets, including Israel.

This agreement will allow Linneo Health to accelerate its growth and progress the development of new cannabinoid profiles or changes in the matrix, along with facilitating Phytocontrol’s first move into the medicinal cannabis sector, with the potential for future service collaborations between both companies.

Don Bellamy, CEO of Linneo Health, stated: “As experts in our relative fields, this collaboration utilizes both Linneo Health’s expertise in the medicinal cannabis sector and Phytocontrol’s leading clinical analysis capabilities. The work we will be doing with Phytocontrol will enable us to expand our reach, ensuring that we can meet the necessary requirements for entry into non-European markets, such as Israel. We’re excited about the potential of this collaboration and look forward to working closely with the Phytocontrol team going forward.”

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo: Benzinga; Sources: courtesy of geralt, lindsayfox via Pixabay

Related News

Linneo Health Expands Medicinal Cannabis Offering With Industrial Cannabis Derivatives